Michael Bowen
Co-Founder & Chief Scientific Officer Kinoxis Therapeutics
Seminars
Wednesday 29th April 2026
Showcase Your Science: Pipeline Innovation Partner Presentations
10:00 am
10.00 – EQL-988: Expanding Rapid Treatment for Suicidality Beyond Ketamine by EQUULUS Therapeutics
10.15 – Building a Best-in-class Cell Therapy for Parkinson’s Disease by Treefrog Therapeutics
10.30 – First-In-Class Inhibitors of ALOX15 for Agitation in Dementia and Pain by Kinoxis Therapeutics
10.45 – A First-in-Class Intranasal Nanobody for Treatment-Resistant Depression by EvoDenovo
11.00 – Olfactory Neurons as a Longitudinal, Molecular Window into Patient Brain Biology by Crownlands
11.15 – MB-204: A Novel A2a Receptor Antagonist to the Restore Social Reward Signal in Autism, Depression & Alzheimer’s Disease by Marvel Biotechnology
11.30 – Presentation by Beacon Neuroscience
Tuesday 28th April 2026
How Advanced Are New Modalities? Where Are the Fields Opening Up?
11:10 am
- Summarizing the field’s progress across disease areas, including the state of play of different modalities. How do you innovate beyond existing MoAs?
- Considerations for the right modality: working with more established technologies versus promising new pharmacokinetics
